Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics. The Glycofect family of reagents has a unique biodegradable composition that provides for efficacious delivery with very low toxicity in key cell types. "We are very pleased to have Nacalai represent Techulon in Japan," said Frank Akers, president at Techulon, "and we look forward to expanding our business in this important market."

“We are excited about the collaboration with Techulon to provide innovative Glycofect products to scientists in Japan”

Nacalai Tesque is a major manufacturer and distributor of life science and chemical research reagents in Japan. Nacalai Tesque has served the Japanese scientific community for more than 160 years through direct sales to researchers in both pharmaceutical industry and academia. "We are excited about the collaboration with Techulon to provide innovative Glycofect products to scientists in Japan," commented Jing Xu, Ph.D., Consultant of Corporate Development at Nacalai USA. "Nacalai's partnership with Techulon demonstrates our long-term commitment and continued leadership in introducing cutting-edge technology to the Japanese scientific research community."

Source:

 Techulon, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Inactivated virion-based vaccine confers robust cell-mediated immunity against major SARS-CoV-2 variants